QuickView for AHSA1;jsessionid=BB00502B7E785F08F8DBB588B0A0C812;jsessionid=8CAE4D2F6D2ADAA7000690C3A4BABDF2;jsessionid=59527D2BB9ADB40D0FF86D690D2CAA77;jsessionid=4611458D3173AC9A7FB1296B151D0C12;jsessionid=636E97E918E33141C83BCCD0DC6CB41A;jsessionid=317EEEFDD7D19702F7E446213DCA5DF0;jsessionid=5CDF123DF387C896489694DC8A7C2E1B;jsessionid=AFFDF922048D66D771667EB48AF7C6A6;jsessionid=5BE00AAC0FA9D5212EF1310D364AFE1C;jsessionid=23F89D02A2CD8EF4A1F4C15EB534A13E;jsessionid=60ADFCF67C26F2EA8899F06EA51889EF (gene)

1. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistan…
2. Hsp90 co-chaperones, FKBP52 and Aha1, promote tau pathogenesis in aged wild-type mice.
3. Co-chaperones TIMP2 and AHA1 Competitively Regulate Extracellular HSP90:Client MMP2 Activity and Mat…
4. A chemical compound inhibiting the Aha1-Hsp90 chaperone complex.
5. Cooperative Nucleotide Binding in Hsp90 and Its Regulation by Aha1.

There were no clinical trials for AHSA1;jsessionid=BB00502B7E785F08F8DBB588B0A0C812;jsessionid=8CAE4D2F6D2ADAA7000690C3A4BABDF2;jsessionid=59527D2BB9ADB40D0FF86D690D2CAA77;jsessionid=4611458D3173AC9A7FB1296B151D0C12;jsessionid=636E97E918E33141C83BCCD0DC6CB41A;jsessionid=317EEEFDD7D19702F7E446213DCA5DF0;jsessionid=5CDF123DF387C896489694DC8A7C2E1B;jsessionid=AFFDF922048D66D771667EB48AF7C6A6;jsessionid=5BE00AAC0FA9D5212EF1310D364AFE1C;jsessionid=23F89D02A2CD8EF4A1F4C15EB534A13E;jsessionid=60ADFCF67C26F2EA8899F06EA51889EF